Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Ran-Anastrozole · DIN 02328690 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2012-12-21 Health Canada: Cancelled post market since 2024-01-22 · brand RAN-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Ranbaxy pharmaceuticals canada inc. · schedule Prescription

DIN 02328690: Ran-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id RAN Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328690 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81420

Interchangeable products

Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.